Meghana Keshavan , 2025-06-20 15:53:00
Contents
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello from the Psychedelic Science Conference in Denver! A fascinating ideological clash underway here, if I do say so myself — counterculture meets corporate science.
Today, we talk about Gilead’s historic approval for HIV prevention, see a U.K. agency reject Alzheimer’s drugs over cost concerns, and hear crickets from the FDA regarding AI-driven medical devices.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
